Updated on 9 May 2012
LCB's technology takes a two-step process: the first is a specific functionalization step at specific amino acid residue and the second is a drug conjugation step at the functionalized position. The method requires a large excess of chemical linkers and drug part, but these reagents can be readily recycled.
With the vision to become a leading pharmaceutical company by holding more than five global clinical pipelines, LCB also offers joint and contract research, chemical library, and screening services for lead identification and optimization based on medicinal chemistry. It provides chemical library packages to research companies for early-ADMET information and customized compound synthesis and services, including in vitro early ADMET screening, metabolic stability tests, protein binding and plasma stability.
Since its inception, LegoChem Biosciences has raised $10 million and is now preparing for an IPO. It expects to be listed with KOSDAQ by mid 2012.
"We believe that the IPO will help us gain improved global competitiveness. With the raised R&D fund, LegoChem will be able to go further in clinical study and drug development to generate more profits, and it will raise the possibility of deals at a global scale," says Dr Yong-Zu Kim.